Being committed to continued advances in improving human health, SCHOTT has opened a new facility in Phoenix, Arizona, to expand the development and manufacturing of diagnostics and life science consumables. Launching the first fully integrated microfluidic foundry in the United States validates SCHOTT’s global growth plan and increases production capabilities to help get these products to market faster and more efficiently. The new, almost 40,000-square-foot facility, comprising of clean room, high volume manufacturing of microarrays and microfluidic devices, allows the company to onshore critical manufacturing supporting the U.S. Government’s renewed interest in reshoring and revitalizing American manufacturing to secure critical domestic supply chains. At the grand opening event on January 9, 2023, speakers from SCHOTT, state, and local government officials, and prominent members of the Phoenix biotech community highlighted the significance of SCHOTT expanding in the U.S.
Phoenix, AZ will mark SCHOTT’s third diagnostics location, with other centers of excellence located in Jena, Germany, and Melbourne, Australia. However, this will be the first location to place a special emphasis on bioscience capabilities using high-density microarrays for diagnostic and life science research. Over the next few years, it will create 150 jobs in the greater Phoenix area, growing SCHOTT MINIFAB’s employee base in Phoenix by 300 percent.
SCHOTT MINIFAB, a diagnostics business of SCHOTT North America, Inc., offers a complete set of solutions for contract design and manufacturing of rapid diagnostics devices to enable precise treatments and therapies.